UBS AM’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $18M | Buy |
555,008
+41,010
| +8% | +$1.33M | ﹤0.01% | 1090 |
|
|
2025
Q1 | $19.4M | Buy |
513,998
+41,034
| +9% | +$1.55M | 0.01% | 981 |
|
|
2024
Q4 | $38.7M | Buy |
472,964
+64,690
| +16% | +$5.3M | 0.01% | 729 |
|
|
2024
Q3 | $46.7M | Buy |
408,274
+112,512
| +38% | +$12.9M | 0.01% | 686 |
|
|
2024
Q2 | $22.3M | Buy |
295,762
+187,750
| +174% | +$14.2M | 0.01% | 827 |
|
|
2024
Q1 | $7.38M | Buy |
108,012
+26,539
| +33% | +$1.81M | ﹤0.01% | 1107 |
|
|
2023
Q4 | $5.12M | Buy |
81,473
+6,975
| +9% | +$438K | ﹤0.01% | 1232 |
|
|
2023
Q3 | $3.8M | Buy |
74,498
+18,467
| +33% | +$941K | ﹤0.01% | 1331 |
|
|
2023
Q2 | $2.1M | Hold |
56,031
| – | – | ﹤0.01% | 1622 |
|
|
2023
Q1 | $2.1M | Buy |
56,031
+4,350
| +8% | +$163K | ﹤0.01% | 1622 |
|
|
2022
Q4 | $2.48M | Buy |
51,681
+17,053
| +49% | +$818K | ﹤0.01% | 1441 |
|
|
2022
Q3 | $831K | Buy |
34,628
+24,296
| +235% | +$583K | ﹤0.01% | 2077 |
|
|
2022
Q2 | $225K | Buy |
+10,332
| New | +$225K | ﹤0.01% | 2558 |
|